Log in

NASDAQ:LUNALuna Innovations Competitors & Alternatives

$5.14
-0.03 (-0.58 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.08
Now: $5.14
$5.26
50-Day Range
$5.32
MA: $6.08
$6.67
52-Week Range
$4.25
Now: $5.14
$9.32
Volume302,900 shs
Average Volume505,972 shs
Market Capitalization$156.72 million
P/E Ratio57.11
Dividend YieldN/A
Beta1.05

Competitors

Luna Innovations (NASDAQ:LUNA) Vs. IQV, INCY, EXAS, PPD, ICLR, and CRL

Should you be buying LUNA stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to Luna Innovations, including Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), and Charles River Laboratories Intl. (CRL).

Iqvia (NYSE:IQV) and Luna Innovations (NASDAQ:LUNA) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Valuation & Earnings

This table compares Iqvia and Luna Innovations' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iqvia$11.09 billion2.46$191 million$5.9424.02
Luna Innovations$70.52 million2.22$5.34 million$0.1730.24

Iqvia has higher revenue and earnings than Luna Innovations. Iqvia is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.6% of Iqvia shares are held by institutional investors. Comparatively, 39.8% of Luna Innovations shares are held by institutional investors. 6.0% of Iqvia shares are held by insiders. Comparatively, 11.2% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Iqvia and Luna Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iqvia1.93%18.48%5.05%
Luna Innovations4.26%6.84%5.39%

Volatility and Risk

Iqvia has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Iqvia and Luna Innovations, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iqvia011602.94
Luna Innovations01102.50

Iqvia currently has a consensus price target of $153.6471, suggesting a potential upside of 7.69%. Luna Innovations has a consensus price target of $8.00, suggesting a potential upside of 55.64%. Given Luna Innovations' higher probable upside, analysts clearly believe Luna Innovations is more favorable than Iqvia.

Summary

Iqvia beats Luna Innovations on 10 of the 14 factors compared between the two stocks.

Incyte (NASDAQ:INCY) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Incyte and Luna Innovations, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Incyte0101302.57
Luna Innovations01102.50

Incyte currently has a consensus price target of $100.65, suggesting a potential downside of 3.92%. Luna Innovations has a consensus price target of $8.00, suggesting a potential upside of 55.64%. Given Luna Innovations' higher possible upside, analysts plainly believe Luna Innovations is more favorable than Incyte.

Insider & Institutional Ownership

91.3% of Incyte shares are held by institutional investors. Comparatively, 39.8% of Luna Innovations shares are held by institutional investors. 16.1% of Incyte shares are held by company insiders. Comparatively, 11.2% of Luna Innovations shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Incyte and Luna Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Incyte-16.87%-12.81%-9.55%
Luna Innovations4.26%6.84%5.39%

Volatility and Risk

Incyte has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Valuation & Earnings

This table compares Incyte and Luna Innovations' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$2.16 billion10.55$446.91 million$2.2346.98
Luna Innovations$70.52 million2.22$5.34 million$0.1730.24

Incyte has higher revenue and earnings than Luna Innovations. Luna Innovations is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Summary

Incyte beats Luna Innovations on 8 of the 13 factors compared between the two stocks.

EXACT Sciences (NASDAQ:EXAS) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares EXACT Sciences and Luna Innovations' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EXACT Sciences$876.29 million15.75$-83,990,000.00($1.49)-61.80
Luna Innovations$70.52 million2.22$5.34 million$0.1730.24

Luna Innovations has lower revenue, but higher earnings than EXACT Sciences. EXACT Sciences is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares EXACT Sciences and Luna Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EXACT Sciences-10.04%-13.98%-7.70%
Luna Innovations4.26%6.84%5.39%

Risk & Volatility

EXACT Sciences has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for EXACT Sciences and Luna Innovations, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
EXACT Sciences001603.00
Luna Innovations01102.50

EXACT Sciences currently has a consensus target price of $107.3333, indicating a potential upside of 16.57%. Luna Innovations has a consensus target price of $8.00, indicating a potential upside of 55.64%. Given Luna Innovations' higher probable upside, analysts plainly believe Luna Innovations is more favorable than EXACT Sciences.

Insider and Institutional Ownership

86.9% of EXACT Sciences shares are owned by institutional investors. Comparatively, 39.8% of Luna Innovations shares are owned by institutional investors. 1.8% of EXACT Sciences shares are owned by company insiders. Comparatively, 11.2% of Luna Innovations shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Luna Innovations beats EXACT Sciences on 8 of the 14 factors compared between the two stocks.

PPD (NASDAQ:PPD) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Profitability

This table compares PPD and Luna Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PPDN/AN/AN/A
Luna Innovations4.26%6.84%5.39%

Institutional and Insider Ownership

65.5% of PPD shares are held by institutional investors. Comparatively, 39.8% of Luna Innovations shares are held by institutional investors. 11.2% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for PPD and Luna Innovations, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PPD001503.00
Luna Innovations01102.50

PPD currently has a consensus target price of $31.1429, indicating a potential upside of 7.06%. Luna Innovations has a consensus target price of $8.00, indicating a potential upside of 55.64%. Given Luna Innovations' higher possible upside, analysts clearly believe Luna Innovations is more favorable than PPD.

Valuation and Earnings

This table compares PPD and Luna Innovations' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PPD$4.03 billion2.52$341.61 million$0.9829.68
Luna Innovations$70.52 million2.22$5.34 million$0.1730.24

PPD has higher revenue and earnings than Luna Innovations. PPD is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Summary

PPD beats Luna Innovations on 7 of the 13 factors compared between the two stocks.

Luna Innovations (NASDAQ:LUNA) and Icon (NASDAQ:ICLR) are both business services companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Risk and Volatility

Luna Innovations has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Icon has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Profitability

This table compares Luna Innovations and Icon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luna Innovations4.26%6.84%5.39%
Icon13.26%24.20%13.46%

Institutional and Insider Ownership

39.8% of Luna Innovations shares are owned by institutional investors. Comparatively, 82.7% of Icon shares are owned by institutional investors. 11.2% of Luna Innovations shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Luna Innovations and Icon, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luna Innovations01102.50
Icon06502.45

Luna Innovations presently has a consensus target price of $8.00, suggesting a potential upside of 55.64%. Icon has a consensus target price of $159.1818, suggesting a potential downside of 8.66%. Given Luna Innovations' stronger consensus rating and higher possible upside, equities research analysts clearly believe Luna Innovations is more favorable than Icon.

Earnings and Valuation

This table compares Luna Innovations and Icon's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luna Innovations$70.52 million2.22$5.34 million$0.1730.24
Icon$2.81 billion3.33$373.99 million$6.8825.33

Icon has higher revenue and earnings than Luna Innovations. Icon is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Summary

Icon beats Luna Innovations on 10 of the 14 factors compared between the two stocks.

Charles River Laboratories Intl. (NYSE:CRL) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Institutional and Insider Ownership

93.1% of Charles River Laboratories Intl. shares are owned by institutional investors. Comparatively, 39.8% of Luna Innovations shares are owned by institutional investors. 1.9% of Charles River Laboratories Intl. shares are owned by insiders. Comparatively, 11.2% of Luna Innovations shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Charles River Laboratories Intl. and Luna Innovations' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Charles River Laboratories Intl.9.09%22.69%7.47%
Luna Innovations4.26%6.84%5.39%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Charles River Laboratories Intl. and Luna Innovations, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Charles River Laboratories Intl.031412.89
Luna Innovations01102.50

Charles River Laboratories Intl. presently has a consensus target price of $176.8333, indicating a potential downside of 2.44%. Luna Innovations has a consensus target price of $8.00, indicating a potential upside of 55.64%. Given Luna Innovations' higher possible upside, analysts plainly believe Luna Innovations is more favorable than Charles River Laboratories Intl..

Valuation and Earnings

This table compares Charles River Laboratories Intl. and Luna Innovations' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Charles River Laboratories Intl.$2.62 billion3.42$252.02 million$6.7326.93
Luna Innovations$70.52 million2.22$5.34 million$0.1730.24

Charles River Laboratories Intl. has higher revenue and earnings than Luna Innovations. Charles River Laboratories Intl. is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Charles River Laboratories Intl. has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Summary

Charles River Laboratories Intl. beats Luna Innovations on 12 of the 15 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Iqvia logo
IQV
Iqvia
1.5$142.68-1.6%$27.69 billion$11.09 billion129.71Analyst Report
Decrease in Short Interest
Incyte logo
INCY
Incyte
1.4$104.76-3.0%$23.45 billion$2.16 billion-59.86Analyst Upgrade
Insider Selling
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$92.08-0.7%$13.80 billion$876.29 million-118.05Analyst Report
Unusual Options Activity
Heavy News Reporting
PPD
PPD
1.9$29.09-0.5%$10.19 billion$4.03 billion29.68
Icon logo
ICLR
Icon
1.6$174.28-1.7%$9.35 billion$2.81 billion25.67Decrease in Short Interest
Charles River Laboratories Intl. logo
CRL
Charles River Laboratories Intl.
1.4$181.25-2.1%$9.16 billion$2.62 billion36.47Analyst Downgrade
Increase in Short Interest
Heavy News Reporting
Exelixis logo
EXEL
Exelixis
1.8$24.94-3.0%$7.42 billion$967.78 million26.82Analyst Report
Increase in Short Interest
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.5$93.45-1.2%$6.03 billion$3.07 billion25.53Decrease in Short Interest
Syneos Health logo
SYNH
Syneos Health
1.5$56.24-0.6%$5.86 billion$4.68 billion30.40Insider Buying
Medpace logo
MEDP
Medpace
1.3$98.18-0.9%$3.51 billion$860.97 million33.86
NRC
National Research
1.0$54.43-2.1%$1.37 billion$127.98 million38.88
Precigen logo
PGEN
Precigen
1.7$4.32-4.2%$743.86 million$90.72 million-2.12Analyst Upgrade
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.4$4.71-1.5%$287.19 millionN/A-10.47Analyst Downgrade
Heavy News Reporting
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$3.06-4.9%$152.25 million$46.28 million-6.51Heavy News Reporting
BASI
Bioanalytical Systems
1.1$4.87-6.2%$52.91 million$43.62 million-25.63Decrease in Short Interest
Heavy News Reporting
Cleveland BioLabs logo
CBLI
Cleveland BioLabs
0.6$2.25-1.3%$25.66 million$1.11 million0.00
TENX
Tenax Therapeutics
1.2$0.93-3.2%$9.21 millionN/A0.00Heavy News Reporting
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.